Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201062 | 0.91 | ALDH1A1 (0.59) | ALDH1A1KMT2AGFERSIGMAR1L3MBTL3 | |
| SCHEMBL17549654 | 0.86 | SIGMAR1 (0.61) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| SCHEMBL5356971 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| SCHEMBL10107784 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL10675086 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL29354698 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| SCHEMBL10507206 | 0.83 | ALDH1A1 (0.96) | ALDH1A1KMT2AGFERSIGMAR1MAPT | |
| Hydrochloric Acid SCHEMBL10670221 | 0.82 | ALDH1A1 (0.97) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| SCHEMBL17549666 | 0.81 | SIGMAR1 (0.73) | ALDH1A1KMT2AGFERSIGMAR1LMNA | |
| SCHEMBL2725965 | 0.80 | KMT2A (0.90) | ALDH1A1KMT2AGFERSIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | ALDH1A1 3775/4885KMT2A 903/4885GFER 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.